161 related articles for article (PubMed ID: 28817437)
1. Surgicopathological Quality Control and Protocol Adherence to Lymphadenectomy in the CRITICS Gastric Cancer Trial.
Claassen YHM; de Steur WO; Hartgrink HH; Dikken JL; van Sandick JW; van Grieken NCT; Cats A; Trip AK; Jansen EPM; Kranenbarg WMM; Braak JPBM; Putter H; van Berge Henegouwen MI; Verheij M; van de Velde CJH
Ann Surg; 2018 Dec; 268(6):1008-1013. PubMed ID: 28817437
[TBL] [Abstract][Full Text] [Related]
2. Impact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial.
Claassen YHM; Hartgrink HH; de Steur WO; Dikken JL; van Sandick JW; van Grieken NCT; Cats A; Trip AK; Jansen EPM; Kranenbarg WMM; Braak JPBM; Putter H; van Berge Henegouwen MI; Verheij M; van de Velde CJH
Gastric Cancer; 2019 Mar; 22(2):369-376. PubMed ID: 30238171
[TBL] [Abstract][Full Text] [Related]
3. Quality control of lymph node dissection in the Dutch Gastric Cancer Trial.
de Steur WO; Hartgrink HH; Dikken JL; Putter H; van de Velde CJ
Br J Surg; 2015 Oct; 102(11):1388-93. PubMed ID: 26313463
[TBL] [Abstract][Full Text] [Related]
4. Association between hospital volume and quality of gastric cancer surgery in the CRITICS trial.
Claassen YHM; van Sandick JW; Hartgrink HH; Dikken JL; De Steur WO; van Grieken NCT; Boot H; Cats A; Trip AK; Jansen EPM; Meershoek-Klein Kranenbarg WM; Braak JPBM; Putter H; van Berge Henegouwen MI; Verheij M; van de Velde CJH
Br J Surg; 2018 May; 105(6):728-735. PubMed ID: 29652082
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
[TBL] [Abstract][Full Text] [Related]
6. Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial.
Claassen YHM; Hartgrink HH; Dikken JL; de Steur WO; van Sandick JW; van Grieken NCT; Cats A; Trip AK; Jansen EPM; Meershoek-Klein Kranenbarg WM; Braak JPBM; Putter H; van Berge Henegouwen MI; Verheij M; van de Velde CJH
Eur J Surg Oncol; 2018 May; 44(5):613-619. PubMed ID: 29503129
[TBL] [Abstract][Full Text] [Related]
7. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
Dikken JL; Jansen EP; Cats A; Bakker B; Hartgrink HH; Kranenbarg EM; Boot H; Putter H; Peeters KC; van de Velde CJ; Verheij M
J Clin Oncol; 2010 May; 28(14):2430-6. PubMed ID: 20368551
[TBL] [Abstract][Full Text] [Related]
8. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
Slagter AE; Jansen EPM; van Laarhoven HWM; van Sandick JW; van Grieken NCT; Sikorska K; Cats A; Muller-Timmermans P; Hulshof MCCM; Boot H; Los M; Beerepoot LV; Peters FPJ; Hospers GAP; van Etten B; Hartgrink HH; van Berge Henegouwen MI; Nieuwenhuijzen GAP; van Hillegersberg R; van der Peet DL; Grabsch HI; Verheij M
BMC Cancer; 2018 Sep; 18(1):877. PubMed ID: 30200910
[TBL] [Abstract][Full Text] [Related]
9. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
Hwang JE; Kim H; Shim HJ; Bae WK; Hwang EC; Jeong O; Ryu SY; Park YK; Cho SH; Chung IJ
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2157-2166. PubMed ID: 31273512
[TBL] [Abstract][Full Text] [Related]
10. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment.
Hundahl SA; Macdonald JS; Benedetti J; Fitzsimmons T;
Ann Surg Oncol; 2002 Apr; 9(3):278-86. PubMed ID: 11923135
[TBL] [Abstract][Full Text] [Related]
11. The essentials of locoregional control in the treatment of gastric cancer.
den Dulk M; Verheij M; Cats A; Jansen EP; Hartgrink HH; Van de Velde CJ
Scand J Surg; 2006; 95(4):236-42. PubMed ID: 17249271
[TBL] [Abstract][Full Text] [Related]
12. Effect of Hospital Volume With Respect to Performing Gastric Cancer Resection on Recurrence and Survival: Results From the CRITICS Trial.
Claassen YHM; van Amelsfoort RM; Hartgrink HH; Dikken JL; de Steur WO; van Sandick JW; van Grieken NCT; Cats A; Boot H; Trip AK; Jansen EPM; Kranenbarg EM; Braak JPBM; Putter H; van Berge Henegouwen MI; Verheij M; van de Velde CJH
Ann Surg; 2019 Dec; 270(6):1096-1102. PubMed ID: 29995679
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.
Ito S; Sano T; Mizusawa J; Takahari D; Katayama H; Katai H; Kawashima Y; Kinoshita T; Terashima M; Nashimoto A; Nakamori M; Onaya H; Sasako M
Gastric Cancer; 2017 Mar; 20(2):322-331. PubMed ID: 27299887
[TBL] [Abstract][Full Text] [Related]
14. Resection for gastric cancer in the community.
van de Velde CJ
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S90-3. PubMed ID: 16399441
[TBL] [Abstract][Full Text] [Related]
15. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.
Songun I; Putter H; Kranenbarg EM; Sasako M; van de Velde CJ
Lancet Oncol; 2010 May; 11(5):439-49. PubMed ID: 20409751
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized controlled trial to compare laparoscopic distal gastrectomy (D2 lymphadenectomy plus complete mesogastrium excision, D2 + CME) with conventional D2 lymphadenectomy for locally advanced gastric adenocarcinoma: study protocol for a randomized controlled trial.
Shen J; Cao B; Wang Y; Xiao A; Qin J; Wu J; Yan Q; Hu Y; Yang C; Cao Z; Hu J; Yin P; Xie D; Gong J
Trials; 2018 Aug; 19(1):432. PubMed ID: 30092843
[TBL] [Abstract][Full Text] [Related]
17. Surgical care quality and oncologic outcome after D2 gastrectomy for gastric cancer.
Mrena J; Mattila A; Böhm J; Jantunen I; Kellokumpu I
World J Gastroenterol; 2015 Dec; 21(47):13294-301. PubMed ID: 26715812
[TBL] [Abstract][Full Text] [Related]
18. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK
J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811
[TBL] [Abstract][Full Text] [Related]
19. Postoperative chemotherapy followed by conformal concomitant chemoradiotherapy in high-risk gastric cancer.
Quero L; Bouchbika Z; Kouto H; Baruch-Hennequin V; Gornet JM; Munoz N; Cojean-Zelek I; Houdart R; Panis Y; Valleur P; Aparicio T; Maylin C; Hennequin C
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):574-80. PubMed ID: 22099038
[TBL] [Abstract][Full Text] [Related]
20. Blast from the past: Perioperative use of the Maruyama computer program for prediction of lymph node involvement in the surgical treatment of gastric cancer following neoadjuvant chemotherapy.
Rawicz-Pruszyński K; Mielko J; Ciseł B; Skórzewska M; Pikuła A; Gęca K; Skoczylas T; Kubiatowski T; Kurylcio A; Polkowski WP
Eur J Surg Oncol; 2019 Oct; 45(10):1957-1963. PubMed ID: 31178298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
